Immune features of the peritumoral stroma in pancreatic ductal adenocarcinoma.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2022
Historique:
received: 18 05 2022
accepted: 22 08 2022
entrez: 22 9 2022
pubmed: 23 9 2022
medline: 24 9 2022
Statut: epublish

Résumé

The peritumoral stroma is a hallmark of pancreatic ductal adenocarcinoma (PDA) with implications for disease development, progression and therapy resistance. We systematically investigated immune features of the stroma in PDA patients to identify markers of clinical importance and potential therapeutic targets. Tissue and blood samples of 51 PDA patients with clinical and follow-up information were included. Laser Capture Microdissection allowed us to analyze the stromal compartment in particular. Systematic immunohistochemistry, followed by software-based image analysis were conducted. Also, multiplex cytokine analyses (including 50 immune-related molecules) were performed. Functional analyses were performed using patient-derived 3D bioprints. Clinical information was used for survival analyses. Intercompartmental IL9 and IL18 gradients were assessed in matched samples of tumor epithelium, stroma, and serum of patients. Serum levels were compared to an age-matched healthy control group. Stromal IL9 and IL18 are significantly associated with patient survival. While IL9 is a prognostic favorable marker (p=0.041), IL18 associates with poor patient outcomes (p=0.030). IL9 correlates with an anti-tumoral cytokine network which connects regulation of T helper (Th) 9, Th1 and Th17 cells (all: p<0.05 and r>0.5). IL18 correlates with a Th1-type cytokine phenotype and stromal CXCL12 expression (all: p<0.05 and r>0.5). Further, IL18 associates with a higher level of exhausted T cells. Inhibition of IL18 results in diminished Th1- and Th2-type cytokines. Patients with high stromal IL9 expression have a tumor-to-stroma IL9 gradient directed towards the stroma (p=0.019). Low IL18 expression associates with a tumor-to-stroma IL18 gradient away from the stroma (p=0.007). PDA patients showed higher serum levels of IL9 than healthy controls while serum IL18 levels were significantly lower than in healthy individuals. The stromal immune cell composition is distinct from the tumor epithelium. Stromal density of FoxP3 An unexpected high expression of the cytokines IL9 and IL18 at different ends is of significance in the stroma of PDA and relates to opposing patient outcomes. Sub-compartmental cytokine analyses highlight the importance of a differentiated gradient assessment. The findings suggest stromal IL9 and/or IL18 as markers for patient stratification and as potential therapeutic targets. Future steps include investigating e. g. the role of local microbiota as both cytokines are also regulated by microbial compositions.

Sections du résumé

Background
The peritumoral stroma is a hallmark of pancreatic ductal adenocarcinoma (PDA) with implications for disease development, progression and therapy resistance. We systematically investigated immune features of the stroma in PDA patients to identify markers of clinical importance and potential therapeutic targets.
Methods
Tissue and blood samples of 51 PDA patients with clinical and follow-up information were included. Laser Capture Microdissection allowed us to analyze the stromal compartment in particular. Systematic immunohistochemistry, followed by software-based image analysis were conducted. Also, multiplex cytokine analyses (including 50 immune-related molecules) were performed. Functional analyses were performed using patient-derived 3D bioprints. Clinical information was used for survival analyses. Intercompartmental IL9 and IL18 gradients were assessed in matched samples of tumor epithelium, stroma, and serum of patients. Serum levels were compared to an age-matched healthy control group.
Results
Stromal IL9 and IL18 are significantly associated with patient survival. While IL9 is a prognostic favorable marker (p=0.041), IL18 associates with poor patient outcomes (p=0.030). IL9 correlates with an anti-tumoral cytokine network which connects regulation of T helper (Th) 9, Th1 and Th17 cells (all: p<0.05 and r>0.5). IL18 correlates with a Th1-type cytokine phenotype and stromal CXCL12 expression (all: p<0.05 and r>0.5). Further, IL18 associates with a higher level of exhausted T cells. Inhibition of IL18 results in diminished Th1- and Th2-type cytokines. Patients with high stromal IL9 expression have a tumor-to-stroma IL9 gradient directed towards the stroma (p=0.019). Low IL18 expression associates with a tumor-to-stroma IL18 gradient away from the stroma (p=0.007). PDA patients showed higher serum levels of IL9 than healthy controls while serum IL18 levels were significantly lower than in healthy individuals. The stromal immune cell composition is distinct from the tumor epithelium. Stromal density of FoxP3
Conclusion
An unexpected high expression of the cytokines IL9 and IL18 at different ends is of significance in the stroma of PDA and relates to opposing patient outcomes. Sub-compartmental cytokine analyses highlight the importance of a differentiated gradient assessment. The findings suggest stromal IL9 and/or IL18 as markers for patient stratification and as potential therapeutic targets. Future steps include investigating e. g. the role of local microbiota as both cytokines are also regulated by microbial compositions.

Identifiants

pubmed: 36131941
doi: 10.3389/fimmu.2022.947407
pmc: PMC9483939
doi:

Substances chimiques

Cytokines 0
Forkhead Transcription Factors 0
Interleukin-18 0
Interleukin-9 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

947407

Informations de copyright

Copyright © 2022 Ahmed, Klotz, Köhler, Giese, Hackert, Springfeld, Jäger and Halama.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

BMC Cancer. 2007 May 23;7:87
pubmed: 17519043
J Clin Oncol. 2009 Jan 10;27(2):186-92
pubmed: 19064967
Cancer Treat Rev. 2020 Jun;86:102016
pubmed: 32247999
J Immunother. 2009 Nov-Dec;32(9):920-31
pubmed: 19816189
Clin Cancer Res. 2016 Dec 1;22(23):5939-5950
pubmed: 27297583
Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12885-90
pubmed: 19433802
Vaccine. 2000 Apr 3;18(19):2002-8
pubmed: 10706961
Am J Respir Crit Care Med. 2012 Dec 1;186(11):1168-79
pubmed: 23065014
Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2265-70
pubmed: 24469818
Cancer Discov. 2020 Mar;10(3):422-439
pubmed: 31911451
Oncoimmunology. 2022 Jan 31;11(1):2027148
pubmed: 35127251
Front Immunol. 2020 May 20;11:1026
pubmed: 32508847
Sci Rep. 2015 Jun 02;5:10665
pubmed: 26035423
Cancer Res. 2011 Sep 1;71(17):5670-7
pubmed: 21846824
Biomed Res Int. 2017;2017:2831056
pubmed: 28349057
Mol Cancer Ther. 2004 Jan;3(1):29-37
pubmed: 14749473
Cells. 2020 Jun 24;9(6):
pubmed: 32599709
Cancer Cell. 2014 Jun 16;25(6):719-34
pubmed: 24856586
Trends Biotechnol. 2022 Apr;40(4):432-447
pubmed: 34556340
Front Immunol. 2021 Apr 06;12:612271
pubmed: 33889150
Front Immunol. 2018 Apr 20;9:763
pubmed: 29731751
Br J Cancer. 2020 Aug;123(4):497-498
pubmed: 32624577
Nature. 2020 Jul;583(7817):609-614
pubmed: 32581358
Cancer Res. 2004 Nov 15;64(22):8420-7
pubmed: 15548713
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Oncoimmunology. 2021 Aug 10;10(1):1962135
pubmed: 34408923
Biofabrication. 2021 Apr 08;13(3):
pubmed: 33524968
Cell. 2015 Dec 3;163(6):1428-43
pubmed: 26638072
Adv Clin Exp Med. 2019 Oct;28(10):1285-1292
pubmed: 31647203
Cytokine Growth Factor Rev. 2019 Dec;50:1-12
pubmed: 31753718
World J Gastroenterol. 2014 Aug 28;20(32):11160-81
pubmed: 25170202
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Pharmaceuticals (Basel). 2021 Aug 10;14(8):
pubmed: 34451884
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Eur J Cancer. 2017 Sep;83:290-301
pubmed: 28772128
Cancer. 2009 Feb 15;115(4):859-68
pubmed: 19140204
Anal Quant Cytol Histol. 2010 Dec;32(6):333-40
pubmed: 21456345
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Br J Cancer. 2010 Nov 23;103(11):1671-9
pubmed: 21045835
Br J Cancer. 2020 Nov;123(10):1469-1470
pubmed: 32843683
Immunity. 2014 Jul 17;41(1):14-20
pubmed: 25035950
Nat Rev Gastroenterol Hepatol. 2012 Aug;9(8):454-67
pubmed: 22710569
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Science. 1996 Nov 8;274(5289):998-1001
pubmed: 8875945
Hum Vaccin Immunother. 2020 Oct 2;16(10):2333-2340
pubmed: 32040369
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
PLoS One. 2009 Nov 16;4(11):e7847
pubmed: 19924291
J Immunother Cancer. 2021 Oct;9(10):
pubmed: 34607895
Chin Med J (Engl). 2013;126(17):3371-4
pubmed: 24033967
Genes Dis. 2015 Jun 1;2(2):133-143
pubmed: 26114155
Cancer Cell. 2016 Apr 11;29(4):587-601
pubmed: 27070705
Br J Cancer. 2020 Aug;123(4):534-541
pubmed: 32499569
Arthritis Rheum. 2007 Jun;56(6):1787-97
pubmed: 17530707

Auteurs

Azaz Ahmed (A)

Translational Immunotherapy (D240), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Medical Oncology and Internal Medicine VI, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
BioQuant, Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.

Rosa Klotz (R)

General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany.

Sophia Köhler (S)

Medical Oncology and Internal Medicine VI, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.

Nathalia Giese (N)

General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany.

Thilo Hackert (T)

General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany.

Christoph Springfeld (C)

Medical Oncology and Internal Medicine VI, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.

Dirk Jäger (D)

Medical Oncology and Internal Medicine VI, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
Applied Tumor Immunity Clinical Cooperation Unit (D120), National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany.

Niels Halama (N)

Translational Immunotherapy (D240), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Medical Oncology and Internal Medicine VI, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
BioQuant, Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
Helmholtz Institute for Translational Oncology Mainz (HI-TRON), Mainz, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH